Metraipolis › archive › dc_eba2dd03fd1e

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United… — Europe PMC PMID:42518569

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42518569
DOI
10.3389/fpubh.2026.1781790
License (as archived)
solo-consultazione
Archived
2026-10-23T15:27:34.275Z
SHA-256 of the archived text
f0902d628d7f6051d4536f844e3029a723cd5dea303309062fed95e6579da6d4
Stable URL of this page
https://metraipolis.com/documento/dc_eba2dd03fd1e

How to cite

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United… — Europe PMC PMID:42518569 — Europe PMC (en), https://europepmc.org/article/MED/42518569 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eba2dd03fd1e (Metraipolis archive dc_eba2dd03fd1e, sha256 f0902d628d7f6051d4536f844e3029a723cd5dea303309062fed95e6579da6d4)
BibTeX
@misc{dceba2dd03fd1e,
  title = {Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United… — Europe PMC PMID:42518569},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42518569},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eba2dd03fd1e; sha256 f0902d628d7f6051d4536f844e3029a723cd5dea303309062fed95e6579da6d4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42518569. Agents can read the archived copy with the MCP tool read_document.